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Summary 
TNF is synthesized as a 26-kD membrane-anchored precursor and is proteolytically processed 
at the cell surface to yield the mature secreted 17-kD polypeptide. The 80-kD tumor necrosis 
factor (TNF) receptor (TNFRs0) is also proteolyticaUy cleaved at the cell surface (shed), releasing 
a soluble ligand-binding receptor fragment. Since processing of TNF and TNFRs0 occurs con- 
currently in activated T cells, we asked whether a common protease may be involved. Here, we 
present evidence that a recently described inhibitor of TNF processing N-{D,t-[2-(hydroxyamino- 
carbonyl)methyl]-4-methylpentanoyl}t-3-(2'naphthyl)-alanyl-I.-alanine, 2-aminoethyl amide (TAPI) 
also blocks shedding of TNFRs0, suggesting that these processes may be coordinately regulated 
during T  cell activation.  In addition, studies  of murine fibroblasts  transfected with human 
TNFRs0, or a cytoplasmic deletion form of TNFRs0, reveal that inhibition of TNFRs0 shedding 
by TAPI is independent of receptor phosphorylation and does not require the receptor cyto- 
plasmic domain, 
T 
NF is a potent mediator of diverse inflammatory and 
immunomodulatory activities necessary for an effective 
host defense (1). However, elevated serum levels of TNF seen 
during many host responses  may be harmful or even fatal 
to the host organism. TNF is initially synthesized as a 26-kD 
type II transmembrane propeptide which is proteolytically 
cleaved at the cell surface, releasing the mature 17-kD cytokine 
assembled as a homotrimer (2). Although both cell surface 
and secreted forms of TNF appear to be biologically active, 
it is soluble TNF released into the circulation which may 
be of primary importance in deleterious physiological  re- 
sponses, such as cachexia or endotoxic shock (3). In support 
of this concept, a potent and selective metalloprotease inhib- 
itor which blocks cleavage of cell surface TNF in activated 
macrophages and T  cells has been shown to reduce serum 
TNF levels and increase survival in endotoxin-treated mice 
(4). More recent evidence indicates that TNF processing is 
mediated by a Zn2+-dependent endopeptidase related to the 
matrix metalloproteases (5,  6). 
Bioavailability of secreted TNF may be regulated, in part, 
by naturally occurring soluble TNF-binding proteins gener- 
ated by proteolytic cleavage (shedding) of cell surface TNF 
receptors  of  55-60  or  75-80  kD  ([TNFR]60,  CD120a; 
TNFRs0,  CD120b,  respectively)  (7,  8).  Shed TNFR can 
function as antagonists of TNF biologic activity by satu- 
rating receptor binding sites on the ligand competitively 
inhibiting interaction with cell surface receptors (9). Other 
evidence suggests that shed TNFR may function as TNF 
agonists, presumably by stabilizing  the TNF trimer at sub- 
saturating concentrations (10). Elevated levels of soluble TNFR 
have been found in body fluids  of patients with elevated 
TNF levels, suggesting a causal relationship between the 
two in various pathologic states (11-18). Furthermore, stim- 
uli that induce production of TNF,  such as activation of 
T cells, also trigger proteolytic cleavage of TNFR in vitro, 
raising the possibility that these processes may be coordinately 
regulated by a common protease  (19). 
Previously, we have shown that activated effector T lym- 
phocytes rapidly downregulate TNFRso by shedding before 
and concurrent with production of TNF (20).  Here,  we 
present evidence that a synthetic, hydroxamic acid-based in- 
hibitor of the TNF processing protease, N-{D,t-[2-(hydroxy- 
aminocarbonyl) methyl]-4-methylpentanoyl}t-3-(2'naphthyl)- 
alanyl-r-alanine, 2-aminoethyl amide (TAPI) (4), is also a potent 
antagonist of TNFI%0 shedding by activated effector T cells. 
These findings support the concept that these two events are 
coordinately regulated and possibly mediated by a common 
cell surface metalloprotease in activated  T  cells. 
Materials  and Methods 
Reagents and Cells.  AU cells were cultured in RPMI  1640 
medium containing 10%  fetal bovine serum, 100 #g/ml strep- 
tomycin and penicillin and 2 raM glutamine (complete medium). 
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centrifugation  (21) and  washed  and  resuspended  in  complete 
medium.  Effector T cells were obtained by culturing  PBMC in 
complete medium containing anti-CD3  (OKT3) for 3 d followed 
by complete medium supplemented with riD2 (10 ng/ml) for 7 d. 
These cells were used as a model for differentiated effector T cells 
and, where indicated, were restimulated with anti-CD3 (20 ng/ml) 
and PMA (10 ng/ml),  as described previously (19). The L929 (mu- 
rine  fibrosarcoma) cell line  stably  expressing  human  TNFRs0 
(LpS0) (19) was cultured in complete medium containing 400/~g/rnl 
G418 (GIBCO, Grand Island, NY). Ionomycin was purchased from 
Sigma Chemical Co.  (St. Louis, MO), and PMA was from LC 
Laboratories (Woburn,  MA). 
Flow Cytoraetry.  Cells were stained with primary mAbs anti- 
TNFI~ (M1) (20) or anti-TNF (104C) at a concentration  of 10 
/~g/ml for 30 rain in ice-cold binding buffer (HBSS supplemented 
with 10% newborn calf serum,  10/~g/ml human  IgG,  20 mM 
Hepes, pH 7.2, and 0.1%  sodium azide). Washed cells were in- 
cubated with PE-conjugated goat anti-murine or goat anti-rat IgG 
(affanity purified, Southern Biotechnology Associates, Birmingham, 
AL)  for  30 min,  washed  twice,  and  analyzed directly  with  a 
FACScan  |  instrument  (Becton Dickinson,  Mountain View, CA). 
Cell viability was >90% as monitored by propidium iodide staining. 
Soluble TNFRso and TNF ELISA.  Human peripheral blood 
T cells (PBT) were isolated via sequential purification with iso- 
lymph, SRBC-rosetting,  and G10 passage, as previously described 
(22) PBT were stimulated with OKT3 (10/~g/ml, solid phase) and 
PMA (10 ng/ml) in the presence or absence of protease inhibitors. 
Protease inhibitors  included  TAPI  (compound  2 in  [4]), trans- 
epoxysuccinyl-t-leucylamido-(4-guanidino)butane  (E64); N-carboxy- 
methyl-Phe-Leu); and ct-l-antitrypsin  (all from Sigma). Soluble 
TNFtG0 and TNF levels were quantitated  from culture superna- 
tants obtained 24 h after activation. TNFlks0 levels were evaluated 
with a commercial ELISA (R & D Systems, Minneapolis, MN). 
Human TNF levels were quantitated  with antibodies derived at 
Immunex  Corp.  (Seattle, WA).  Briefly, maxisorp plates (Nunc, 
Roskilde, Denmark) were incubated overnight with anti-TNF mAb 
(5 #g/ml). The plates were washed with PBS Tween, and the sam- 
ples were incubated for I h at room temperature. The plates were 
washed and incubated  for  1 h with  a  1:500 dilution  of rabbit 
anti-human  TNF (P3 ab; Immunex)  in PBS Tween containing 
5% normal goat serum. The plates were then washed and incu- 
bated with a 1:8,000 dilution  of horseradish peroxidase-conjug- 
ated donkey  anti-rabbit  IgG  (Jackson ImmunoResearch  Labs., 
Inc., West Grove, PA) and were developed with tetramethyl benzi- 
dine (TMB) substrate system (Kirkegaard and Perry Laboratories 
Inc., Gaithersburg,  MD). 
Metabolic Labeling and Immunotrrecipitation.  For pulse-chase anal- 
),sis, effector T  cells (5  x  106/ml) washed in RPMI  1640 and 
lacking cysteine and methionine  were labeled for 30 rain  with 
3sS-Cys/Met (160/~Ci/ml),  then chased in complete medium for 
various times. Supernatants  and detergent  extracts of cells were 
prepared for immunoprecipitation with anti-TNFlaq0 (M1) or anti- 
TNF (104C) and subjected to SDS-PAGE as described (20). For 
32p04 labeling, L929-TNFRs0 stable transfectants (1.5 x  107/ml) 
washed in phosphate-free RPMI 1640 were labeled for 60 min with 
carrier-free 32PO4 (0.5 mCi/ml), lysed, and prepared for immuno- 
precipitation  using M1 as described (19). 
Radioimmunometric Assay.  Surface  TNFIks0 in L929-TNFIKs0 
stable transfectants  was measured by binding  125I-anti-TNFRs0 
mAb (M1), as described  previously (19). Briefly, cells were incubated 
with 500 pM 1~I-M1 for 1 h at 4~  Nonspecific binding was de- 
termined by incubation  in the presence of 200-fold molar excess 
of unlabeled M1. Unbound mAb was removed by four washes with 
cold  binding  buffer  and  bound  mAb  quantitated  by  gamma 
counting. 
Results and Discussion 
TAPI Inhibits TNF Release and TNFRso Shedding in Acti- 
vated T Lymphocytes.  Resting effector T cells (activated 7 d 
earlier with anti-CD3) do not secrete detectable levels of TNF 
and do not express any surface TNF detectable by flow cyto- 
metry (Fig.  1 A). However, within 2 h of reactivation, using 
a combination of phorbol ester (PMA) and calcium iono- 
phore, abundant surface TNF was present. Consistent with 
previous findings (4), surface TNF expression is greatly en- 
hanced when  effector T  cells  are activated in  the presence 
of TAPI,  reflecting inhibition  of TNF processing. 
In contrast to TNF, resting effector T cells constitutively 
express TNFRs0 on their surfaces.  However, reactivation of 
these cells with PMA/calcium  ionophore or PMA/OKT3 
triggers rapid downregulation of TNFRs0 (Fig.  1, B and C 
[20]). In the presence of TAPI, activation-induced loss of sur- 
face TNFRs0 was significantly inhibited (Fig.  1, B and C). 
A time-course analysis of effector T cells activated with phorbol 
ester and anti-CD3 (PMA/OKT3) confirmed that TAPI in- 
hibits  downregulation  of TNFRs0  (Fig.  1 D).  However, 
TNFRs0 surface expression diminishes even in the presence 
of TAPI, albeit more slowly and incompletely than cells not 
treated with  TAPI. 
Previous studies have established that downregulation of 
TNFRs0 in  activated effector T  cells occurs by shedding, 
releasing a soluble fragment of the receptor from the cell sur- 
face (20).  To determine if the inhibition of TNFRs0 down- 
regulation  seen in the presence of TAPI is due to blockade 
of shedding, soluble TNFRs0 production was quantitated by 
ELISA. As shown in Fig. 2 A, TAPI caused a dose-dependent 
reduction in the amount  of soluble TNFRs0 detectable in 
culture supernatants from activated T  cells. In the presence 
of 200/~M  TAPI,  shedding  of TNFRs0 was inhibited by 
~80%.  The  concentration  of  TAPI  necessary  for  half- 
maximal inhibition of TNFRs0 shedding is between 25 and 
50 #M, which is comparable to the concentration required 
for half-maximal  inhibition  of TNF  release  (~,50/zM)  by 
these same cells (4). In addition, examination of various pro- 
tease inhibitors showed that those which do not block TNF 
release by activated T  cells also fail to prevent TNFRs0 shed- 
ding  (Fig.  2 B),  further  supporting  the hypothesis that  a 
similar  protease mediates both of these processes. 
Pulse-chase Analysis of TNF and TNFRso Processing in Ac- 
tivated T  Cells.  To investigate  the effect of TAPI on syn- 
thesis  and  processing  of TNF  and  TNFRs0  by  activated 
effector T  cells in more detail, a pulse-chase labeling experi- 
ment  was performed  (Fig.  3).  To  study TNF  processing, 
effector T cells activated for 1 h with PMA/OKT3 were pulse- 
labeled for 30 min with 3sS-Cys/Met in the presence or ab- 
sence of TAPI, then chased with unlabeled Cys/Met. As ex- 
pected, the 26-kD TNF propeptide was immunoprecipitated 
only from cell lysates,  whereas the 17-kD secreted form of 
TNF was detected only in the supernatant  (Fig.  3 A). The 
rapid loss of 26-kD  cell-associated TNF  during  the chase 
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the supematant, but not intraceUularly, indicates that the TNF 
propeptide  is processed to the 17-kD form primarily  at the 
cell surface. In contrast,  when the pulse-chase is performed 
in the presence of TAPI  (Fig.  3 B),  cell-associated-26-kD 
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Figure  1.  Enhanced expression of surface TNF  and  inhibition  of 
TNFKs0 downregulation in activated effector T cells. PBT cells activated 
with OKT3 and cultured in IL-2  for 7 d were reactivated with a combina- 
tion of PMA and ionomycin (.4 and B) or PMA/OKT3 (C) in the pres- 
ence or absence of TAPI (200 #M). After 2 h, cells were harvested from 
culture and incubated on ice with either anti-TNF antiserum (A), or anti- 
TNFR.s0 mAb (B and C) for 30 min, then stained with PE-conjugated 
goat anti-mouse  or anti-rat IgG for 30 min, as described in Materials 
and Methods. (D) PBT cells cultured as described above and reactivated 
with a combination of PMA and OKT3 in the presence (O) or absence 
(O) of TAPI (200 #M) were harvested from culture at various times and 
incubated with anti-TNFRs0 mAb, then stained with PE-conjugated goat 
anti-rat IgG for analysis by flow cytometry. 
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Figure  2.  Inhibition of secreted TNF and soluble TNFKs0 production 
by TAPI. Human PBTC were stimulated with plate-bound OKT3 and 
PMA in the presence of (.4) various concentrations of TAPI or (B) other 
protease inhibitors (50/tM); ~t-antitrypsin was at 1/zg/ml. Supernatants 
were harvested and the levels of TNF and soluble TNFRso determined 
by ELISA. [] TNF,  ￿9  TNFRs0. 
TNF accumulates, but no secreted 17-kD TNF is detected, 
demonstrating  that TAPI is acting at the cell surface to in- 
hibit  TNF  processing.  Accumulation  of the  26-kD  cell- 
associated polypeptide is followed by a gradual  decrease in 
the density of its autoradiographic signal after 20 min, which 
probably reflects a decrease in specific activity as a consequence 
of continued protein synthesis during the chase and indicates 
that  TAPI is not  inhibiting  protein  synthesis. 
Activated effector T  cells rapidly downregulate  TNFKs0 
by proteolytic processing of the mature 80-kD protein at the 
cell surface,  releasing  a  soluble 40-kD  fragment  of the ex- 
tracellular domain (Fig. 3 C) (20). In the presence of TAPI, 
however, cell-associated 80-kD TNFR polypeptide accumu- 
lates and no soluble 40-kD fragment is detected in the super- 
natant,  even after 80 rain,  confirming that proteolytic pro- 
cessing of TNFKs0 is inhibited  (Fig.  3 D).  In spite of this, 
processing of the  70-kD  TNFRs0  precursor protein  to the 
1207  Crowe et al.  Brief Definitive Report Figure 3.  Inhibition  of TNF and TNFP,  z0 processing in activated  T lymphocytes  by TAPI. Effector  T cells incubated with PMA/anti-CD3 for 
60 min were pulse-labeled  for 30 min with 3sS-Cys/Met  in the absence (A) or presence (B) of TAPI (200 #M), then chased  with complete  medium 
_+ TAPI. At various times,  an aliquot of cells was centrifuged,  and TNF immunoprecipitated  from the cell-free  supernatants  or from  cell lysates,  using 
rabbit anti-TNF antiserum, was resolved  by SDS-PAGE (12% gel) and autoradiography  (8-d exposure). Processed TNF lacks two met residues, ac- 
counting for the lower autoradiographic  band density  relative to the 26-kD form. Effector  T cells were pulse-labeled  for 30 min with 3sS-Cys/Met 
in the absence (C) or presence (D) of TAPI (200 #M), then chased with complete medium containing  PMA/anti-CD3 + TAPI. At various times, 
an aliquot of cells was centrifuged  to prepare cell lysates  and cell-free  supernatants  for immunoprecipitation,  using  anti-TNFRs0  mAb (M1). TNFR.s0 
was resolved  by SDS-PAGE (10% gel) and autoradiography  of the dried gel (10-d exposure). 
80-kD form continues in the presence of TAPI, demonstrating 
that maturation of TNFKso is not inhibited. Collectively, 
these findings clearly show that TAPI inhibits shedding of 
TNFI%o and suggest that  the initial inhibition of down- 
regulation seen by flow cytometric analysis is also due to in- 
hibition of shedding. The incongruity  between surface staining 
and measurement of soluble receptor levels at later time points 
indicates  that, when shedding is blocked, TNFKs0 may be 
downregulated by an alternate process. In this regard, muta- 
tions in TNFRs,0, which inhibit proteolytic cleavage, do not 
block downregulation in response to PMA, indicating that 
multiple mechanisms for downregulating TNFR are opera- 
tive (23). Furthermore, we have observed that TAPI has no 
effect on expression  of CD4 which is downregulated by in- 
ternalization after T  cell activation (24), but TAPI partially 
inhibits downregulation of TNFK60, which is also subject 
to proteolytic cleavage (25) (data not shown) on neutrophils. 
TAPI Inhibits Shedding of TNFRso in L929-TNFRso--stable 
Transfectants.  To further investigate the mechanism of inhi- 
bition  of  TNFKs0  shedding  in  a  more  defined  cellular 
system, mouse L929  cells  stably transfected with  human 
TNFRs0 (LpS0) were activated  with phorbol ester  (PMA, 
100 ng/ml) for 30 min in the presence or absence of TAPI, 
and surface TNFRs0 levels were detected by a radioimmuno- 
metric binding assay, using anti-TNFRs0 mAb. As shown 
in Table 1, LpS0 shed ~73% of their receptors after stimula- 
tion with PMA, whereas, in the presence of TAPI, they shed 
only "~27%  of their TNFKs0 (63%  inhibition). Thus, the 
protease  which regulates shedding of human TNFtLso  ex- 
pressed in mouse cells is also sensitive to inhibition by TAPI. 
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TNFRs0 expression 
(12SI-M1 bound,  cpm) 
Control  TAPI 
Lp80  -PMA  21,909 +_ 212  20,466  +_  297 
+ PMA  5,872 +  206  (73)  14,973 +  417 (27) 
Lp80Acyt  -PMA  20,807 _+  1,012  21,572  _+  861 
+PMA  12,415 +  624 (40)  17,762 _+  118 (18) 
Cells (1.5 x  10S/well  in 24-well plates) were preincubated  with media 
only (control), and, then, TAPI (20/~M) for 90 min at 37~  before 
activation with PMA (100 ng/ml) for 30 rain. Specific lzSI-M1  binding 
was determined by incubating  cells with 12SI-M1 (500 pM) for 1 h at 
4~  The results shown  are means _+ SEM of two separate experiments. 
Nonspecific binding  cpm determined  in the presence of 200-fold excess 
unlabeled  M1 were 1,743 _+ 106 for Lp80, and 2,289 :t: 52 for Lp80Acyt. 
Numbers in parentheses represent percent loss of specific 12SI-M1 bind- 
ing compared to unactivated  cells. 
Previously, we have shown that TNFRs0 is constitutively 
phosphorylated and that phosphorylation is a late processing 
event which precedes proteolytic cleavage of TNFRs0 (19). 
In addition, constitutive phosphorylation and shedding of 
TNFRs0 were blocked by the protein kinase inhibitor stauro- 
sporine,  suggesting a link between receptor phosphorylation 
and proteolysis. As observed in Fig. 3 D, the gradual increase 
in apparent  molecular mass  of T  ceU-associated  TNFRs0 
in the presence  of TAPI suggested that phosphorylation of 
TNFRs0 continues, even though shedding is blocked. How- 
ever, to directly examine whether TAPI affects phosphoryla- 
tion of TNFRs0, Lp80 cells were labeled with [32p]-ortho- 
phosphate in the presence or absence of TAPI before treatment 
with PMA. Cell extracts were then subjected to immuno- 
precipitation using M1. As shown in Fig.  4, TAPI did not 
inhibit constitutive phosphorylation of TNFRs0,  but did 
block activation-induced loss ofphosphorylated receptor.  To 
confirm that inhibition of TNFRs0  shedding by TAPI is 
independent of  receptor phosphorylation, L929 cells expressing 
a mutant form of the receptor lacking the entire cytoplasmic 
domain (LpSOAcyt) were tested for activation-induced loss 
of TNFRs0 in the presence  or absence of TAPI.  Truncated 
Figure 4.  L929-TNFRs0  stable transfectants  were washed  in phosphate- 
free medium, labeled  with [32P]-orthophosphate  for 2 h, then  incubated 
without (lanes 1 and 2) or with (lanes 3 and 4) TAPI for 5 rain before 
addition of PMA (100 ng/ml) (lanes 2 and 4), or nothing (lanes I and 
3). After  30 min further  incubation,  detergent  extracts  of cells were sub- 
jected to immunoprecipitation  with anti-TNFRs0 mAb followed  by SDS- 
PAGE (8% gel) and autoradiography  (5-h exposure). 
TNFRs0 expressed by these cells is not phosphorylated but 
is shed in response  to PMA, albeit more slowly and incom- 
pletely compared to cells expressing  the full-length receptor 
(19).  As  seen  in Table  1,  LpSOAcyt  shed ~40%  of their 
TNFP,  s0,  but,  in  the presence  of TAPI only, *18%  was 
shed (55% inhibition), clearly demonstrating that inhibition 
of TNFRso shedding by TAPI does not involve the receptor 
cytoplasmic domain, and, therefore, is independent of  receptor 
phosphorylation. 
In conclusion, the data presented here show that a cell- 
surface metaUoprotease  is involved in shedding of TNFP,  s0 
by activated T  lymphocytes. Furthermore, the observation 
that TNF processing and TNFRs0 shedding occur concur- 
rently and are similarly sensitive to inhibition by TAPI strongly 
suggests that these processes are coordinately regulated during 
T ceU activation. Notably, the protease cleavage site in TNF 
(Ala-Val)  is  also  present  in  the  extracellular  domain  of 
TNFR.s0 (Ala213-Va1214) at a site consistent with the observed 
molecular weight of the shed receptor fragment (26). Thus, 
metalloprotease inhibitors such as TAPI may offer protection 
from the deleterious systemic effects of TNF at two levels 
simultaneously: first, by preventing the release of  soluble TNF, 
and second, by blocking accumulation of shed TNFR; soluble 
TNFR has been shown to stabilize  TNF activity in vitro 
(10). It will be of  interest to determine whether other members 
of the TNF ligand family or the TNFR family are also sub- 
ject to coordinated proteolytic processing. 
The authors would like to thank Bruce Hess and Michelle Seaberg for excellent technical assistance and 
Dr. Jeffrey Browning (Biogen, Inc.) for the gift of anti-TNF mAb 104C. 
This work was supported by grants to C. F. Ware from the American Cancer Society, Inc. (IM663) and 
the Cigarette and Tobacco Surtax Fund of the State of California through the Tobacco-related  Diseases 
Research Program (RT0261) and Public Health Service grant, National Institutes of  Health RO1 AI33068. 
Address correspondence to Dr. Carl F. Ware, Division of Biomedical Sciences, University of California, 
Riverside, CA 92521. The current address for Dr. Paul  D. Crowe is Neurocrine Biosciences, Inc., 3050 
Science Park Road, San Diego, CA 92121-1102. 
Received for publication 17 October 1994. 
1209  Crowe  et al.  Brief  Definitive Report References 
1.  Tracey, K.J,, and A. Cerami. 1993. Tumor necrosis factor, other 
cytokines and disease. Annu.  Rev. Cell Biol. 9:317-343. 
2.  Kriegler, M., C. Perez, K. DeFay, I. Albert, and S.D. Lu. 1988. 
A novel form of TNF/cachectin is a cell surface cytotoxic trans- 
membrane protein: ramifications  for the complex physiology 
of TNF. Cell. 53:45-53. 
3.  Perez, C., I. Albert, K. DeFay, N. Zachariades, L. Gooding, 
and M. Kriegler. 1990. A nonsecretable cell surface mutant 
of tumor necrosis factor (TNF) kills by cell-to-cell  contact. 
Cell. 63:251-258. 
4.  Mohler, K.M., P.K. Sleath, J.N. Fitzner, D.P. Cerretti, M. 
Alderson,  S.S. Kerwar,  D.S.  Torrance,  C.  Otten-Evans,  T. 
Greenstreet, and K. Weerawarna.  1994. Protection against  a 
lethal dose of endotoxin by an inhibitor of tumour necrosis 
factor processing.  Nature (Lond,). 370:218-220. 
5.  Gearing, A.J., P. Beckett, M. Christodoulou, M. Churchill, 
J. Clements, A.H. Davidson, A.H. Drummond, W.A. Gal- 
loway, Ik. Gilbert, andJ.L. Gordon. 1994. Processing of tumour 
necrosis factor-alpha  precursor by metaUoproteinases.  Nature 
(Lond.). 370:555-557. 
6.  McGeehan, G.M., J.D. Becherer, K.C. Bast, C.M. Boyer, B. 
Champion, K.M. Connolly, J.G. Conway, P. Furdon, S. Karp, 
and S. Kidao. 1994. Regulation of turnout necrosis factor-alpha 
processing  by a metalloproteinase inhibitor.  Nature  (Lond.). 
370:558-561. 
7.  Nophar, Y., O. Kemper, C. Brakebusch, H. Englemann, K. 
Zwang,  D.  Aderka,  H.  Holtmann,  and D.  Wallach.  1990. 
Soluble forms of tumor necrosis factor receptors (TNF-Ks). 
The cDNA for the type I TNF-R, cloned using amino acid 
sequence data of its soluble form, encodes both the cell surface 
and a soluble  form of the receptor. EMBO (Eur. Mol. Biol. 
Organ.).],  9:3269-3278. 
8.  HeUer, K.A., K. Song, M.A. Onasch, W.H. Fischer, D. Chang, 
and G.M. Ringold.  1990. Complementary DNA cloning of 
a receptor for tumor necrosis factor and demonstration of a 
shed  form of the receptor. Proc. Natl.  Acad. Sci. USA.  87: 
6151-6155. 
9.  Van Zee, K.J., T. Kohno, E. Fischer,  C.S.  Rock, L.L. Mol- 
dawer,  and S.F. Lowry. 1992. Tumor necrosis factor soluble 
receptors circulate during experimental and clinical inflamma- 
tion and can protect against excessive tumor necrosis factor 
alpha  in vitro and in vivo. Proc. Natl.  Acad. Sci. USA.  89: 
4845-4849. 
10.  Aderka, D., H. Engelmann, Y. Maor, C. Brakebusch,  and D. 
Wallach. 1992. Stabilization of the bioactivity of tumor necrosis 
factor by its soluble  receptors. J. Exi~ Med.  175:323-329. 
11.  Gatanaga, T., C.D.  Hwang,  W.  Kohr, F. Cappuccini, J.A. 
Lucci, E.W. Jeffes, K. Lentz, J. Tomich, K.S. Yamamoto,  and 
G.A. Granger. 1990. Purification and characterization of an 
inhibitor (soluble  tumor necrosis factor receptor) for tumor 
necrosis  factor and  lymphotoxin obtained from the  serum 
ultrafiltrates of human cancer patients. Proc. Natl. Acad. Sci. 
USA.  87:8781-8784. 
12.  Aderka, D., H. Englemann, V. Hornik, Y. Skornick, Y. Levo, 
D. Wallach,  and G. Kushtai. 1991. Increased  serum levels of 
soluble receptors for tumor necrosis factor in cancer patients. 
Cancer Res. 51:5602-5607. 
13.  Aderka,  D.,  A.  Wysenbeek, H. Engelmann,  A.P.  Cope, F. 
Brennan, Y. Molad, V. Hornik, Y. Levo, K.N. Maini, M. Feld- 
mann, et al. 1993. Correlation between serum levels of soluble 
tumor necrosis factor receptor and disease activity in systemic 
lupus erythematosus. Arthritis Rheum.  36:1111-1120. 
14.  Godfried, M.H., T. van der Poll, J. Jansen, J.A. Romijin, J.K. 
Schattenkerk, E. Endert, S.J. van Deventer, and H.P. Sauer- 
wein. 1993. Soluble receptors for turnout necrosis factor: a puta- 
tive marker of disease progression in HIV infection. AIDS 
(Phila.). 7:33-36. 
15.  Olsson, L., M. Lantz, E. Nilsson, C. Peetre, H. Thysell, A. 
Grubb, and G. Adolf.  1989. Isolation and characterization of 
a tumor necrosis factor binding protein from urine. Eur.J. Hae- 
matol. 42:270-275. 
16.  Brockhaus, M., Y. Bar-Khayim, S. Gurwicz, A. Frensdorff, 
and N.  Haran.  1992.  Plasma  tumor necrosis  factor soluble 
receptors in chronic renal failure. Kidney Int.  42:663-667. 
17.  Cope,  A.P.,  D.  Aderka,  M.  Doherty,  H.  Engelmann,  D. 
Gibbons, A.C. Jones, F,M. Brennan, K.N. Maini, D. Wallach, 
and M.  Feldmann.  1992.  Increased  levels of soluble  tumor 
necrosis factor receptors in the sera and synovial fluid of pa- 
tients with rheumatic diseases, Arthritis Rheum. 35:1160-1169. 
18.  Deleuran,  B.W.,  C.Q.  Chu,  M.  Field,  F.M.  Brennan,  T. 
Mitchell, M. Feldmann, and K.N. Maini.  1992. Localization 
of tumor necrosis factor receptors in the synovial tissue  and 
cartilage-pannus junction in patients with rheumatoid arthritis. 
Implications for local actions of tumor necrosis factor alpha. 
Arthritis Rheum.  35:1170-1178. 
19.  Crowe, P.D., T.L. VanArsdale, K.G. Goodwin, and C.F. Ware. 
1993.  Specific induction  of 80-kDa  tumor  necrosis  factor 
receptor shedding in T lymphocytes involves the cytoplasmic 
domain and phosphorylation. J. Immunol.  151:6882-6890. 
20.  Ware, C.F., P.D. Crowe, T.L. VanArsdale, J.L. Andrews, M.H. 
Grayson, K. Jerzy, C.A.  Smith,  and K.G. Goodwin.  1991. 
Tumor necrosis factor (TNF) receptor expression in T  lym- 
phocytes. Differential regulation of the type I TNF receptor 
during activation of resting and effector T cells. J. Immunol. 
147:4229-4238. 
21.  Andrews, J.S., A.E. Berger, and C.F. Ware.  1990. Character- 
ization of the receptor for tumor necrosis factor (TNF) and 
lymphotoxin (LT) on human T lymphocytes. TNF and LT differ 
in their receptor binding properties and the induction of MHC 
class I proteins on a human CD4+  T cell hybridoma.J. Ira- 
munol. 144:2582-2591. 
22.  Armitage, K.J., B.M. Macduff, S.F. Ziegler, and K.H. Grab- 
stein.  1992.  Multiple cytokine secretion by IL-7-stimulated 
human T  cells. Cytokine.  4:461-467. 
23.  Gullberg,  U.,  M.  Lantz,  L.  LindvaU,  I.  Olsson,  and  A. 
Himmler. 1992. Involvement of an Asn/Val cleavage site in 
the production of a soluble form of a human tumor necrosis 
factor (TNF) receptor. Site-directed  mutagenesis of a putative 
cleavage site in the p55 TNF receptor chain. Eur.J. Celt Biol. 
58:307-312. 
24.  Hoxie. J.A., D.M. Matthews, K.J. Callahan, D.L. Cassel, and 
R.A. Cooper. 1986. Transient modulation and internalization 
of  T4  antigen  induced  by  phorbol  esters.  J.  Immunol. 
137:1194-1201. 
25.  Porteu, F., and C. Nathan. 1990. Shedding of tumor necrosis 
factor receptors by activated human neutrophils. J. Exp. Med. 
172:599-607. 
26.  Smith, C.A., T. Davis, D. Anderson, L. Solam,  M.P. Beck- 
mann, K. Jerzy, S.K. Dower, D. Cosman, and K.G. Goodwin. 
1990. A receptor for tumor necrosis factor defines an unusual 
family of cellular and viral proteins. Science (Wash. DC). 248: 
1019-1023. 
1210  An Inhibitor of TNF Receptor Shedding 